The cell line is not validated yet.
SDQLCHi083-A
General
Cell Line |
|
hPSCreg name | SDQLCHi083-A |
Cite as: | SDQLCHi083-A (RRID:CVCL_E3CJ) |
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | No similar lines found. |
Last update | 2nd December 2024 |
User feedback | |
Provider |
|
Generator | Children’s Hospital affiliated to Shandong University (SDQLCH) |
Owner | Children's Hospital affiliated to Shandong University (SDQLCH) |
Derivation country | China |
External Databases |
|
Cellosaurus | CVCL_E3CJ |
BioSamples | SAMEA117428525 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | female |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA117428526 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | y_liu99@sina.com |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Alternatives to consent are available? | No |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | Unknown |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | No |
Does consent expressly prevent the derivation of pluripotent stem cells? | Yes |
Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | Yes |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | Yes |
Does consent expressly prevent development of commercial products? | Yes |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
a non-profit company? | Yes |
a for-profit corporation? | No |
Does consent expressly permit collection of genetic information? | No |
Does consent expressly permit storage of genetic information? | No |
Does consent prevent dissemination of genetic information? | No |
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | Yes |
How may genetic information associated with the cell line be accessed? | Open Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Does consent permit access to medical records of the donor? | Yes |
Please describe how access is provided: | This study was approved by the Medical Ethics Committee of Children's Hospital affiliated to Shandong University |
Does consent permit access to any other source of information about the clinical treatment or health of the donor? | Yes |
Contact data, institution, or website: | Children’s Hospital Affiliated to Shandong University |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Medical Ethics Committee of Children’s Hospital Affiliated to Shandong University |
Approval number | SFFE-IRB/P-2023055 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | No |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
Is there an MTA available for the cell line? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Stem Cell Technologies |
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
Source cell type |
Mononuclear cells collected from peripheral blood.
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Methods used |
PCR
|
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
None
|
Other |
|
Selection criteria for clones | morphology |
Derived under xeno-free conditions |
Yes |
Derived under GMP? |
Yes |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method | digestion with EDTA |
CO2 Concentration | 5 % |
Medium |
Other medium:
Base medium: ncTarget® basal Medium
Main protein source: ncTarget® Supplement A & ncTarget® Supplement B Serum concentration: 20 % |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|||||
TRA 1-81 |
Yes |
|||||
SSEA-4 |
Yes |
|||||
NANOG |
Yes |
Marker | Present | Absent |
mCpG | ||
OCT4 | X |
Self-renewal
Unknown
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46, XX
Passage number: 17
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.